Search for: "ASTRAZENECA LP"
Results 21 - 40
of 155
Sort by Relevance
|
Sort by Date
15 Apr 2016, 8:26 am
These medications are available by prescription and over-the-counter (OTC) from various pharmaceutical companies, for example: PRILOSEC (omeprazole magnesium) | prescription drug | AstraZeneca LPPRILOSEC OTC (omeprazole magnesium) | over-the-counter | Procter & Gamble Manufacturing Co.PREVACID (lansoprazole) | prescription drug | Takeda Pharmaceuticals America, Inc.PREVACID 24 HR (lansoprazole) | over-the-counter | Novartis Consumer Health, Inc.NEXIUM (esomeprazole magnesium) |… [read post]
25 Mar 2016, 3:16 pm
AstraZeneca Pharm. [read post]
21 Dec 2015, 5:43 pm
” AstraZeneca LP v. [read post]
18 Dec 2015, 9:19 am
AstraZeneca Pharm. [read post]
17 Dec 2015, 11:54 am
Patents in his portfolio include US Patent Numbers 6,331,400, 6,771,291, 7,353,199, 7,996,259, 8,335,713, 8,412,570, 8,417,567, 8,423,399, 8,442,860, 8,589,222, 8,650,076, 8,768,760, 8,781,890 and 8,996,398.[8] = = = = = [1] US patent Application No. 10/868,312, claim number 24. [2] See 1 Chisum on Patents section 1.02. [3] In re Russell, 48 F.2d 668, 669 (CCPA 1931)(indexing the names in directories and dictionaries). [4] AstraZeneca LP v. [read post]
8 Dec 2015, 2:22 pm
AstraZeneca LP and Cephalon Inc. paid the United States $26.7 million and $4.3 million, respectively, in separate settlements for allegedly underpaying rebates owed under the Medicaid Drug Rebate Program. [read post]
9 Sep 2015, 6:11 am
The Department of Justice announced settlements in the following False Claims Act lawsuits: AstraZeneca and Cephalon to Pay $46.5 Million and $7.5 Million, Respectively, for Allegedly Underpaying Rebates Owed Under Medicaid Drug Rebate Program AstraZeneca LP has agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program, the Justice… [read post]
8 Apr 2015, 3:41 pm
AstraZeneca Pharm., LP, 634 F.3d 1352, 1362 (11th Cir. 2011) (“Several considerations shape the physician’s medical judgment, including both individual patient concerns and drug-specific information regarding the propriety of a drug’s use for treatment of a patient’s given condition . . . [read post]
27 Feb 2015, 5:02 am
AstraZeneca to Pay $7.9 Million to Resolve Kickback Allegations AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act. [read post]
13 Feb 2015, 12:00 pm
AstraZeneca LP et al. was filed under seal on behalf of the federal government in October 2010 by former AstraZeneca employees Paul DiMattia and F. [read post]
17 Nov 2014, 9:59 pm
AstraZeneca Pharmaceuticals LP et al. v. [read post]
13 Nov 2014, 5:00 am
Courtesy of Mike Imbroscio of Covington (who was on the winning team) today’s post is about a very satisfying Cymbalta win – not only did warning causation fail under the learned intermediary rule, but the warning for the drug was held adequate as a matter of law. [read post]
26 Oct 2014, 9:17 pm
AstraZeneca Pharmaceuticals LP et al. v. [read post]
23 Jun 2014, 12:57 pm
ITERATIVE DISJUNCTIVE SYLLOGISM Basic propositional logic teaches that the disjunctive syllogism (modus tollendo ponens) is a valid argument, in which one of its premises is a disjunction (P v Q), and the other premise is the negation of one of the disjuncts: P v Q ~P_____ ∴ Q See Irving Copi & Carl Cohen Introduction to Logic at 362 (2005). [read post]
3 May 2014, 8:56 am
After a long winter, the cherry trees are finally managing to blossom. [read post]
23 Apr 2014, 7:44 am
” See also AstraZeneca LP v. [read post]
8 Dec 2013, 8:02 pm
Aurobindo Pharma Ltd. et al. 3:13-cv-07298; filed December 3, 2013 in the District Court of New Jersey • Plaintiffs: Astrazeneca AB; Aktiebolaget Hassle; Astrazeneca LP; KBI Inc.; KBI-E Inc. [read post]
13 Nov 2013, 9:14 pm
By Donald Zuhn -- In an appeal decided last month, the Federal Circuit reversed and remanded a decision of noninfringement by the District Court for the District of New Jersey with respect to U.S. [read post]
27 Oct 2013, 9:55 pm
Lupin Ltd. et al. 3:13-cv-06315; filed October 23, 2013 in the District Court of New Jersey • Plaintiffs: Astrazeneca AB; Astrazeneca LP; KBI-E Inc.; Pozen, Inc. [read post]
25 Oct 2013, 3:56 am
In the court’s view, this circumstantial evidence of a “pattern of antagonism” raised an inference of retaliation and was enough to support her Title VII claim (Brangman v AstraZeneca, LP). [read post]
